🔗 Share this article

A shadow market for unlicensed weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.

Experimental Drug Gaining Traction Via Social Media

Retatrutide, which remains in research studies, is being promoted by social media influencers for its alleged fat-burning properties. Followers are urged to contact these profiles directly for source information, while also obtaining promotional offers.

Thriving Trade on Social Networks

Separately, a flourishing market exists on Telegram, where communities with numerous of members share “before and after” images, administration instructions and assertions of next-day British shipping. Sellers promote the substance there before directing buyers to WhatsApp for transactions.

Learning About Retatrutide

Retatrutide is an experimental injectable created by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could assist individuals lose up to 25% of their total weight. Nicknamed the “triple G”, the drug is being promoted digitally as the next Ozempic.

Healthcare Experts Express Concerns

However, physicians and chemists have cautions that the distribution of what is still an unlicensed drug in the UK is a cause for concern and could result in individuals administering substances of uncertain source.

Some experts said the popularity for retatrutide could be linked to the rising price of approved weight loss treatments such as Mounjaro.

Regulatory Position and Enforcement

Marketing the unapproved drug on social media or Telegram is illegal in the United Kingdom, as it is an unlicensed medication that cannot be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Some content creators attempt to sidestep the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and distribution can still violate pharmaceutical, advertising, and customer regulations, risking fines, legal action or prison.

Platform Response and Content Elimination

According to the social media company, the platform has taken down violative content and banned associated keywords and query recommendations. The company stated it was dedicated to maintaining the platform secure and investing in enhancing compliance measures.

Online Trading Operations

Research also found groups with up to nine thousand participants selling the experimental drug using the platform's built-in discovery tool, which operates like a online catalog. Typing “retatrutide” immediately brings up groups with thousands of users, populated with images of slimming results, positive reviews and step-by-step instructions for preparing or injecting at residence.

After minutes of entering one group, a vendor shared contact information, where most transactions occur. The vendor provided an guidebook and promised shipping within 48 hours. When asked whether the substance was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a supposed testing documentation. None inquired about body mass, medical conditions or previous experience.

Item Information and Pricing

Within these communities, posts display dark colored packages with postal service labels, stating to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, mixed at residence with purified liquid, or ready-to-use pens typically sold at 160 pounds for 20 milligrams. When asked how much time a injector should last, vendors give contradictory responses varying between a few weeks to “depends on your body”.

Service Moderation and Safety Actions

A spokesperson for the messaging service said it actively moderated harmful material on its platform including content that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Medical Expert Cautions

“People are administering substances they cannot confirm. Although the research behind this drug is valid, these online products may not include what they claim,” said Jason Murphy, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of an online medical service connected the surge in interest to current cost increases for authorized weight-loss medications such as Mounjaro. “With prices increasing, patients are using social media. But fake treatments are extremely dangerous. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she explained.

Her team has already seen individuals injured by self-injection from unconfirmed suppliers. “We understand the disappointment, but buying from messaging apps or WhatsApp is taking chances with your health,” stated the doctor. “These materials could be contaminated or incorrectly dosed.”

Producer Position

A spokesperson from Eli Lilly said the substance was in third stage research studies and had not been reviewed or approved by any regulatory agency globally. “Consequently at this point no one can sell [it] for personal consumption,” they explained, adding that any item “falsely representing itself as a Lilly experimental substance not yet approved … may subject users to potentially significant medical dangers”.